• Profile
Close

Prophylactic effect of dexamethasone on regorafenib-related fatigue and/or malaise: A randomized, placebo-controlled, double-blind clinical study in patients with unresectable metastatic colorectal cancer (KSCC1402/HGCSG1402)

Oncology Mar 10, 2018

Tanioka H, et al. - Regorafenib is an oral multikinase inhibitor with a proven survival benefit for metastatic colorectal cancer patients. The prophylactic effect of oral dexamethasone (DEX) on regorafenib-related fatigue and/or malaise was investigated. The clinical efficacy of prophylactic oral DEX in improving regorafenib-related fatigue and/or malaise was demonstrated.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay